Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21 waf1/cip1on the SP-B resistance or susceptibility of human leukemia cells

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 862-868

  Kanno, Syu Ichi ^a   Maeda, Naoyuki ^a   Tomizawa, Ayako ^a   Yomogida, Shin ^a   Katoh, Tadashi ^a   Ishikawa, Masaaki ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Drug resistant; Histone deacetylase inhibitor; P21waf1 cip1; Spiruchostatin

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; FAS ANTIGEN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; ROMIDEPSIN; SPIRUCHOSTATIN B; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL STRAIN K 562; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; DRUG STRUCTURE; ERYTHROLEUKEMIA; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEPSIPEPTIDES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE TRANSFER TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA; PACLITAXEL; RNA, MESSENGER; VINCRISTINE;

EID: 84864969896     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1507     Document Type: Article

References (32)

1. Narita K, Kikuchi T, Watanabe K, et al: Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5″-epi- spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity. Chemistry 15: 11174-11186, 2009.
2. Ocker M and Schneider-Stock R: Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 39: 1367-1374, 2007. (Pubitemid 47031035)
3. Xiong Y, Zhang H and Beach D: D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505-514, 1992.
4. Han JW, Ahn SH, Kim YK, et al: Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J Biol Chem 276: 42084-42090, 2001.
5. Fournel M, Trachy-Bourget MC, Yan PT, et al: Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 62: 4325-4330, 2002. (Pubitemid 34827289)
6. Archer SY, Meng S, Shei A and Hodin RA: p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791-6796, 1998.
7. Sambucetti LC, Fischer DD, Zabludoff S, et al: Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274: 34940-34947, 1999. (Pubitemid 129509542)
8. waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells. Int J Oncol 40: 1391-1396, 2012.
9. Szakacs G, Annereau JP, Lababidi S, et al: Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6: 129-137, 2004. (Pubitemid 39485685)
10. Xiao JJ, Huang Y, Dai Z, et al: Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diiso propyl-2-oxa-12,13-dithia-5, 8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 314: 467-475, 2005. (Pubitemid 41058285)
11. Yamada H, Arakawa Y, Saito S, Agawa M, Kano Y and Horiguchi-Yamada J: Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile. Leuk Res 30: 723-734, 2006.
12. Matsubara H, Watanabe M, Imai T, et al: Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21- bis(propan-2-yl)-2-oxa-12,13-dit hia-5,8,20,23-tetraazabicyclo[8.7.6] tricos-16-ene-3,6,9,19,22-pentone]. J Pharmacol Exp Ther 328: 839-848, 2009.
13. Imesch P, Dedes KJ, Furlato M, Fink D and Fedier A: MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. Int J Oncol 35: 631-640, 2009.
14. Dedes KJ, Dedes I, Imesch P, von Bueren AO, Fink D and Fedier A: Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs 20: 321-333, 2009.
15. Takizawa T, Watanabe K, Narita K, Oguchi T, Abe H and Katoh T: Total synthesis of spiruchostatin B, a potent histone deacetylase inhibitor, from a microorganism. Chem Commun (Camb): 1677-1679, 2008. (Pubitemid 351441902)
16. Kanno S, Kakuta M, Kitajima Y, et al: Preventive effect of trimidox on oxidative stress in U937 cell line. Biol Pharm Bull 30: 994-998, 2007. (Pubitemid 46708638)
17. Kanno S, Hiura T, Ohtake T, et al: Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells. Clin Chim Acta 377: 144-149, 2007. (Pubitemid 44908246)
18. Kanno S, Higurashi A, Watanabe Y, Shouji A, Asou K and Ishikawa M: Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell lines. Toxicol Lett 152: 149-158, 2004. (Pubitemid 39061766)
19. Song JH, Choi CH, Yeom HJ, Hwang SY and Kim TS: Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis. Life Sci 79: 193-202, 2006. (Pubitemid 43737068)
20. Li W, Fan J, Banerjee D and Bertino JR: Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol Pharmacol 55: 1088-1093, 1999. (Pubitemid 29252376)
21. Ahmed W, Rahmani M, Dent P and Grant S: The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells. Cell Cycle 3: 1305-1311, 2004. (Pubitemid 40268614)
22. Fiskus W, Rao R, Fernandez P, et al: Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 112: 2896-2905, 2008.
23. Bandyopadhyay D, Mishra A and Medrano EE: Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 64: 7706-7710, 2004. (Pubitemid 39446901)
24. Condorelli F, Gnemmi I, Vallario A, Genazzani AA and Canonico PL: Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 153: 657-668, 2008. (Pubitemid 351271755)
25. Vrana JA, Decker RH, Johnson CR, et al: Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18: 7016-7025, 1999. (Pubitemid 30028872)
26. Insinga A, Monestiroli S, Ronzoni S, et al: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76, 2005. (Pubitemid 40215840)
27. Sasakawa Y, Naoe Y, Inoue T, et al: Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett 195: 161-168, 2003. (Pubitemid 36588965)
28. Peart MJ, Smyth GK, van Laar RK, et al: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 3697-3702, 2005. (Pubitemid 40354674)
29. Imai T, Adachi S, Nishijo K, et al: FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 22: 9231-9242, 2003. (Pubitemid 38122035)
30. Liu S, Bishop WR and Liu M: Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 6: 183-195, 2003. (Pubitemid 37129918)
31. Law JC, Ritke MK, Yalowich JC, Leder GH and Ferrell RE: Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res 17: 1045-1050, 1993. (Pubitemid 23358335)
32. Filippini G, Griffin S, Uhr M, et al: A novel flow cytometric method for the quantification of p53 gene expression. Cytometry 31: 180-186, 1998. (Pubitemid 28113898)